Argenx's stock surged 16.66% following positive Phase III ALKIVIA trial results for its autoimmune drug Vyvgart Hytrulo, showing significant efficacy in treating autoimmune myositis. Analyst firm William Blair reaffirmed an 'Outperform' rating, reflecting strong confidence in the company's future. The successful trial marks a major milestone for Vyvgart DM, targeting dermatomyositis, and boosts investor optimism with Argenx's market value reaching about $61.76 billion. This development highlights Argenx's growing role in autoimmune disease treatment innovation.
InspireMD reported better-than-expected Q2 results with a loss per share of -$0.17, improving from last year and beating estimates. Revenue reached $1.77 million, driven by strong 21% growth in international markets for its CGuard platform. The compa...
EyePoint Pharmaceuticals' stock dropped sharply after its wet AMD drug DURAVYU missed the primary trial endpoint, though an adjusted analysis showed it matched the standard treatment and cut treatment burden by 42%. Despite the setback, a Jefferies a...
H World Group reported better-than-expected Q2 2026 results, with earnings per share of $0.78 surpassing the $0.74 estimate and revenue of $1.05 billion exceeding forecasts. The company saw a 10.8% year-over-year revenue increase, driven mainly by a ...
Rocket Lab successfully launched eight satellites for MDA Space as part of a $143 million deal, boosting revenue to $234.07 million, above analyst expectations. Despite this operational success, the company reported a negative EPS of -$0.08, missing ...
Alpha Cognition reported a strong Q2 2026 with revenue rising to $6.1 million, up from $1.7 million a year earlier, beating estimates by 41%. This growth was driven by high demand for its Alzheimer's drug ZUNVEYL, which accounted for nearly all reven...
